124 related articles for article (PubMed ID: 38043062)
1. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
Guo Y; Tian J; Guo Y; Wang C; Chen C; Cai S; Yu W; Sun B; Yan J; Li Z; Fan J; Qi Q; Zhang D; Jin W; Hua Z; Chen G
Cell Rep; 2023 Dec; 42(12):113511. PubMed ID: 38043062
[TBL] [Abstract][Full Text] [Related]
2. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
3. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
4. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
6. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
7. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
8. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
9. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
[TBL] [Abstract][Full Text] [Related]
11. Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer.
Chiang CY; Fan S; Zheng H; Guo W; Zheng Z; Sun Y; Zhong C; Zeng J; Li S; Zhang M; Xiao T; Zheng D
Cell Rep; 2023 Sep; 42(9):113003. PubMed ID: 37682707
[TBL] [Abstract][Full Text] [Related]
12. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
13. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
14. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
15. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
17. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
[No Abstract] [Full Text] [Related]
18. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
19. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
